共查询到20条相似文献,搜索用时 136 毫秒
1.
三种三联疗法对HP阳性的消化性溃疡的疗效和治疗成本的比较 总被引:1,自引:0,他引:1
本研究比较了三种三联疗法对HP阳性的消化性溃疡(Pu)的疗效和治疗成本。59例病人经内镜确诊为PU,组织学和(或)^12C(或^14C)呼吸试验证实HP阳性,随机进入三种低剂量三联根除方案。所有病人在治疗开始后第六周复查内镜并作组织学检查和(或)^13C(或^13C)呼吸试验以评价溃疡愈合和HP根除情况。结果表明:方案3(雷尼替丁0.15Bid 灭滴灵0.2Qid 羟氨苄青霉素0.25Qid连用两周,续用雷尼替丁0.15Bid两周)的溃疡愈合率HP根除率和副反应发生率分别为95.2%、85.7%,14.3%,均优于另两方案(方案1:次枸橼酸胶态铋(CBS)120mg Qid 灭滴灵0.2Qid 四环素0.25Qid,连用两周.方案2:同方案1,仅以羟氨苄青霉素0.25Qid代替四环素),但治疗成本略高。三种方案的上述指标的差异均无显性(P>0.05)。 相似文献
2.
3.
目的:观察10d序贯疗法治疗幽门螺杆菌(Helicobacter pylori,H.pylori)的疗效及不良反应,与14d三联标准疗法比较H.pylori根除情况及经济学上有无优越性.方法:将103例经胃镜检查确诊为慢性胃炎或消化性溃疡且H.pylori阳性的患者随机分为两组,治疗组(10d序贯疗法)52例,前5d埃索美拉唑、阿莫西林,后5d埃索美拉唑、克拉霉素、替硝唑.对照组(14d标准三联疗法)51例,埃索美拉唑、阿莫西林、克拉霉素14d.所有患者停药4wk后复查13C呼气试验或胃镜检查,判断H.pylori根除情况.结果:治疗组H.pylori根除率为90.4%,与对照组(90.2%)比较无统计学差异(P=1.000);两组不良反应发生率分别为12/52(23.1%)、18/51(35.3%),两组比较无统计学差异(P=0.172);治疗组费用为380.6元,较对照组(677.88元)明显减低.结论:10d序贯疗法的H.pylori根除率不低于标准14d三联疗法,2组不良反应发生率相似,但10d序贯疗法根除H.pylori的效价比更高. 相似文献
4.
三联疗法治疗HP相关性出血性十二指肠溃疡的远期疗效观察 总被引:1,自引:0,他引:1
目的;观察三联疗法根除幽门螺杆菌,预防溃疡复发与再出血的远期疗效。方法:选择有HP感染的出血性十二指肠溃疡患者58例,随机分为两组。治疗组36例,用丽珠得乐冲剂,呋喃唑酮片剂,泰胃美片治疗2周;对照组22例,单用泰胃美片治疗2周,疗程结束后,两组患者均再用泰胃美治疗2周。总疗程结束后4周及每半年复查胃镜和HP,定期随访2年。 相似文献
5.
目的研究布拉氏酵母菌(S.boulardii)联合标准三联疗法治疗幽门螺杆菌阳性消化性溃疡的临床疗效与价值。方法选取幽门螺杆菌阳性消化性溃疡120例。随机分为A组及B组。各60例,A组使用标准三联疗法进行治疗;B组患者在A组基础上联用布拉氏酵母菌治疗。比较两组治疗效果、不良反应及幽门螺杆菌根除率等指标。结果 B组患者总有效率及幽门螺杆菌根除率分别是98.3%,90.3%,显著优于A组患者90.0%,81.70%;不良反应人数比较显示B组显著少于A组患者(P0.05)。结论布拉氏酵母菌联合标准三联疗法有效提高幽门螺杆菌的根除率,减少药物的不良反应。 相似文献
6.
7.
目的:观察三联疗法根除幽门螺杆菌(HP),预防溃疡复发与再出血的远期疗效。方法:选择有HP感染的出血性十二指肠溃疡患者58 例,随机分为两组。治疗组36 例,用丽珠得乐冲剂、呋喃唑酮片剂、泰胃美片治疗2周;对照组22例,单用泰胃美片治疗2周。疗程结束后,两组患者均再用泰胃美治疗2 周,总疗程结束后4 周及每半年复查胃镜和HP,定期随访2 年。结果:治疗组和对照组溃疡愈合率分别为100% 和81.8% ,HP根除率分别为80.5% 和9.1% 。随访2 年后,治疗组溃疡复发率为13.9% ,再出血率为5.5% ,对照组溃疡复发率为90.9% ,再出血率为45.4% ,两组溃疡复发率与再出血率比较有显著性差异( P< 0.05)。结论:三联疗法具有较好的根除HP、明显减少溃疡复发和再出血发生的作用,具有较好的远期疗效 相似文献
8.
近年来 ,我们联合应用雷尼替丁、羟氨苄西林、甲硝唑治疗幽门螺杆菌 (HP)阳性的 5 6例上消化道溃疡患者。现报告如下 ,并观察其对 HP的根除效果及十二指肠溃疡的愈合情况。一般资料 :本组 5 6例均为内镜检查确诊为上消化道溃疡且 HP阳性者 ,男 4 2例 ,女 14例 ;平均年龄 39± 4 相似文献
9.
目的探讨奥美拉唑三联疗法治疗幽门螺杆菌(Hp)相关性消化性溃疡(PU)的疗效。方法选取60例Hp阳性的消化性溃疡患者,随机分为治疗组与对照组,每组30例。治疗组予以奥美拉唑胶囊、阿莫西林胶囊和甲硝唑三联治疗,对照组予以雷贝拉唑钠、阿莫西林和甲硝唑片三联治疗。均为饭前口服,连续服用2周。治疗结束后4周,观察两组临床症状改善情况,并通过胃镜检查,观察溃疡愈合率及Hp根除率。结果治疗组溃疡愈合率为80.0%,有效率为13.3%,总有效率为93.3%;对照组溃疡愈合率为73.3%,有效率为16.7%,总有效率为90.0%,两组比较差异无统计学意义(P0.05)。治疗组Hp根除率为90.0%,对照组Hp根除率为93.3%,两组比较差异无统计学意义(P0.05)。结论奥美拉唑、阿莫西林、甲硝唑三联疗法治疗Hp相关性消化性溃疡具有疗效好、疗程短、依从性好、费用低的优点,适合基层医院推广应用。 相似文献
10.
埃索美拉唑新三联疗法治疗Hp阳性老年消化性溃疡疗效观察 总被引:2,自引:0,他引:2
消化性溃疡(PU)是临床常见病、多发病,老年性PU是指年龄60岁以上的PU患者。幽门螺杆菌(Hp)感染是老年性PU发病的重要致病因素,近年发现Hp耐药性增强。2006年3~9月,我们通过观察埃美索拉唑、左氧氟沙星、阿莫西林短程三联疗法对Hp阳性PU的治疗效果,寻求一种价格低廉、疗效高、耐药率低的抗Hp方案。 相似文献
11.
目的观察不同疗程奥美拉唑三联方案根除幽门螺杆菌(Hp)后的复发率。方法Hp阳性的干二指肠溃疡103例患者,随机分为二组:A组50例;B组53例。均给予奥美拉唑20 mg(每日2次)、阿莫西林1.0 g(每日2次)、呋喃唑酮0.1 g(每日3次),A组疗程2周,B组疗程1周。观察2组Hp根除率、溃疡复发率、3年Hp复发率及不良反应。结果A组Hp根除率、溃疡愈合率、Hp根除者3年累积复发率分别为92.0%、96.0%、8.7%;B组分别为88.7%、92.5%、12.8%,两组三项差异均无显著性(P>0.05)。结论1周和2周疗程方案近、远期疗效相同,但1周疗程方案疗程短,病人依从性好,费用减半,效-价比优于2 周疗程方案。 相似文献
12.
AIM: To compare a lansoprazole-based triple versus quadruple therapy for Helicobacter pylori (H pylori) eradication with emphasis on side effect profile, patient compliance and eradication rate at a rural district general hospital in Wales, United Kingdom. METHODS: One hundred one patients with H pylori infection were included in the study. Patients were randomised to receive triple therapy comprising of lansoprazole 30 mg, amoxycillin 1 g, clarithromycin 500 mg, all b.d. (LAC), or quadruple therapy comprising of lansoprazole 30 mg b.d., metronidazole 500 mg t.d.s., bismuth subcitrate 240 mg b.d., and tetracycline chloride 500 mg q.d.s. (LMBT). Cure was defined as a negative 13C urea breath test 2 mo after treatment. RESULTS: Seven patients were withdrawn after randomisation. Fifty patients were assigned to LAC group and 44 to LMBT group. The intention-to-treat cure rates were 92% and 91%, whereas the perprotocol cure rates were 92% and 97%, respectively. Side effects were common, with 56% experiencingmoderate to severe symptoms in the LAC group and 59% in the LMBT group. Symptoms of vomiting, diarrhoea and black stools were significantly more common in the LMBT group. Patient compliance was 100% for triple therapy and 86% for quadruple therapy (P 〈 0.01). One-third of patients in both groups were still taking acid-reducing medications at six-month follow-up. CONCLUSION: One-week triple and quadruple therapies have similar intention-to-treat eradication rates. Certain side effects are more common with quadruple therapy, which can compromise patient compliance. Patient education or modifications to the regimen are alternative options to improve compliance of the quadruple regimen. 相似文献
13.
毫米波加药物治疗Hp+消化性溃疡50例 总被引:2,自引:0,他引:2
目的探讨幽门螺杆菌阳性(Hp+)的消化性溃疡(PU)愈合和复发的物理治疗(毫米波mmW)及其联合药物治疗的前景.方法本组PU93例采用mmW辐射探头对PU患者体表胃投影区照射30min,(n=50)每日1~2次,联合药物(甲哨唑+西咪替丁)在Hp+的PU愈合和复发的疗效进行研究,并与对照组43例进行比较.结果mmW治疗及联合药物治疗组与对照组单用药物H2受体阻滞剂西咪替丁相比较,结果治疗组溃疡愈合率及Hp根除率100%(50/50)及98%(49/50).1年后复发率为4%(2/50);而对照组溃疡愈合率905%(38/43),Hp根除率508%(25/43),1年后复发率209%(9/43).说明Hp根除与溃疡复发有一定关系,2组相比有显著差异(P<005~001).结论mmV联合药物治疗Hp+PU愈合和复发优于单用H2受体阻滞剂. 相似文献
14.
目的研究胃溃疡患者使用三联7天疗法治疗幽门螺杆菌(Helicobacter pylori,H.pylori)感染的根除率,评估患者依从性、年龄、性别对于此类人群根除H.pylori治疗的影响。方法将经胃镜检查确诊为新发胃溃疡,并经活组织病理学检查明确有H.py-lori感染的1 075例患者纳入研究范围,所有入选患者均接受三联(洛赛克或耐信20 mg/次、2次/天,联合克拉霉素500 mg/次、2次/天,与阿莫西林1 000 mg/次、2次/天)7天疗法行根除H.pylori治疗,之后予以耐信或洛赛克20 mg/次、1次/天、治疗49天。所有入选患者系统治疗完成后6-8周复查胃镜。结果40-59岁与60岁以上人群的胃溃疡患者对治疗的依从性差异无显著性,而40岁以下人群对治疗的依从性较差(P〈0.05)。〈40岁、40-59岁和≥60岁胃溃疡患者的H.pylori根除率分别为61.0%、72.7%和81.9%。〈40岁与40-59岁和≥60岁患者的H.pylori根除率差异有统计学意义(P〈0.05)。不同性别胃溃疡患者的H.pylori根除率差异无显著性(P〉0.05)。结论使用三联7天疗法治疗胃溃疡患者的H.pylori感染,H.pylori的根除率较低,患者对治疗的依从性、年龄是影响胃溃疡患者H.pylori根除率的重要因素,而性别对此无影响。 相似文献
15.
10天序贯疗法与标准三联疗法治疗幽门螺杆菌感染荟萃分析 总被引:16,自引:1,他引:16
目的系统地评价10天序贯疗法能否获得比标准三联疗法更高的H.pylori根除率,以及两种方案之间发生副反应的差异。方法利用中英文检索词检索相关电子数据库,根据纳入标准入选了比较10天序贯疗法与标准三联疗法的幽门螺杆菌根除率的随机临床试验。提取患者基本资料、研究质量、H.pylori根除率和副作用的发生率等相关数据。针对于10天序贯疗法和7天或10天标准三联疗法的H.pylori根除率和副作用的发生率,计算相应的RR和95%可信区间。运用漏斗图评价出版偏倚。结果Meta分析纳入了10项随机对照研究,共2855例患者。10天序贯疗法明显优于7天或10天标准三联疗法,总的H.pylori根除率分别为93.5%、75.9%和79.4%,RR为1.23(95%CI=1.19—1.28)和1.16(95%CI:1.10—1.23)。无论是溃疡性消化不良患者还是非溃疡性消化不良患者,10天序贯疗法都能获得更高的H.pylori根除率,RR分别为1.16(95%CI=1.10—1.23)和1.26(95%CI=1.19—1.33);针对克拉霉素耐药患者,10天序贯疗法的有效H.pylori根除率也高于标准三联疗法(75.9%vs32.7%),RR为2.18(95%CI=1.43—3.34)。然而两种方案副作用的发生率无明显差别(RR=1.00,95%CI=0.97—1.03)。结论10天序贯疗法明显优于7天或10天标准三联疗法,副作用无明显增加。 相似文献
16.
奥美拉唑或兰索拉唑、阿莫西林、呋喃唑酮短程三联疗法根除幽门螺杆菌 总被引:14,自引:1,他引:13
目的探索根除率较高、价廉、安全实用的HP根除方案.方法137例消化性溃疡或糜烂性胃窦炎患者,随机分为3组A组44例,以奥美拉唑20mg+克拉霉素250mg+替硝唑500mg每天2次,疗程7天,即Bazzoli方案;B组47例,以奥美拉唑20mg+阿莫西林1000mg+呋喃唑酮100mg,每天2次,疗程7天;C组46例,以兰索拉唑30mg每天1次,阿莫西林1000mg+呋喃唑酮100mg每天2次,疗程7天.活动期溃疡患者抗HP治疗后继服奥美拉唑20mg或兰索拉唑30mg,每天1次,3周.抗HP治疗结束1月后复查胃镜并检测HP.结果A、B、C3组的HP根除率分别为90.9%、87.2%和89.1%;活动期溃疡愈合率分别为100%、93.8%和100%;糜烂性胃窦炎愈合率分别为85.2%、79.2%和92.2%;副反应发生率分别为13.6%、6.4%和8.7%.各组间差异无显著性,P>0.05.A、B、C3组每例抗HP所需费用分别为544.5元、309.0元和170.5元.结论方案B、C是2种新的、根除率较高、价廉、安全实用的HP根除方案. 相似文献
17.
Eradication of H pylori infection in a rural population: One-day quadruple therapy versus 7-day triple therapy 总被引:5,自引:2,他引:3
Zhang L Shen L Ma JL Pan KF Liu WD Li J Xiao SD Lin SR Classen M You WC 《World journal of gastroenterology : WJG》2006,12(24):3915-3918
AIM: To compare the one-day quadruple therapy with a standard 7-d triple therapy for H pylori eradication in a rural population of China. METHODS: A total of 396 patients with 13C-urea breath test positive for H pylori were assigned into two groups: 239 patients received one-day quadruple therapy (amox icillin 2000 mg qid; metronidazole 500 mg qid; bismuth citrate 900 mg qid and lansoprazole 60 mg once daily) and 157 patients received 7-d standard triple therapy (amoxicillin 1000 mg bid; clarithromycin 500 mg bid and lansoprazole 30 mg bid). All the patients underwent a 13C-UBT to assess the eradication of H pylori infection six weeks after treatment. RESULTS: Two hundred and twenty-nine patients completed the one-day therapy (95.8%) and 148 patients completed the 7-d therapy (94.2%). The one day therapy eradicated H pylori infection in 64 patients (27.95%). In contrast, 103 patients (69.59%) were H pylori negative after the 7-d therapy (P < 0.01). CONCLUSION: This pilot study suggests there is no beneficial effect of the one-day therapy in treatment of H pylori infection compared with the 7-d standard therapy. 相似文献
18.
Jae Jin Hwang Dong Ho Lee Ae-Ra Lee Hyuk Yoon Cheol Min Shin Young Soo Park Nayoung Kim 《World journal of gastroenterology : WJG》2015,21(16):4954-4960
AIM:To evaluate the incidence and clinical characteristics of gastric cancer(GC) in peptic ulcer patients with Helicobacter pylori(H.pylori) infection.METHODS:Between January 2003 and December 2013, the medical records of patients diagnosed with GC were retrospectively reviewed.Those with previous gastric ulcer(GU) and H.pylori infection were assigned to the Hp GU-GC group(n = 86) and those with previous duodenal ulcer(DU) disease and H.pylori infection were assigned to the Hp DUGC group(n = 35).The incidence rates of GC in the Hp GU-GC and Hp DU-GC groups were analyzed.Data on demographics(age, gender, peptic ulcer complications and cancer treatment), GC clinical characteristics [location, pathological diagnosis, differentiation, T stage, Lauren's classification, atrophy of surrounding mucosa and intestinal metaplasia(IM)], outcome of eradication therapy for H.pylori infection, esophagogastroduodenoscopy number and the duration until GC onset were reviewed.Univariate and multivariate analyses were performed to identify factors influencing GC development.The relative risk of GC was evaluated using a Cox proportional hazards model.RESULTS:The incidence rates of GC were 3.60%(86/2387) in the Hp GU-GC group and 1.66%(35/2098) in the Hp DU-GC group.The annual incidence was 0.41% in the Hp GU-GC group and 0.11% in the Hp DUGC group.The rates of moderate-to-severe atrophy of the surrounding mucosa and IM were higher in the Hp GU-GC group than in the Hp DU-GC group(86% vs 34.3%, respectively, and 61.6% vs 14.3%, respectively, P 0.05).In the univariate analysis, atrophy of surrounding mucosa, IM and eradication therapy for H.pylori infection were significantly associated with the development of GC(P 0.05).There was no significant difference in the prognosis of GC patients between the Hp GU-GC and Hp DU-GC groups(P = 0.347).The relative risk of GC development in the Hp GUGC group compared to that of the Hp DU-GC group,after correction for age and gender,was 1.71(95%CI:1.09-2.70;P=0.02).CONCLUSION:GU patients with H.pylori infection had higher GC incidence rates and relative risks.Atrophy of surrounding mucosa,IM and eradication therapy were associated with GC. 相似文献
19.
Kim HW Kim GH Cheong JY Yang US Park SK Song CS Kang DH Song GA 《World journal of gastroenterology : WJG》2008,14(6):908-912
AIM: To investigate whether adding ecabet sodium to the standard triple therapy for H pylori infection improve eradication rate. METHODS: Two hundred and fifty-seven H pylori-infected patients were randomly assigned to standard triple therapy (group A, n = 129) or triple therapy plus ecabet sodium (group B, n = 128). Successful eradication was defined as a negative 13C-urea breath test 6-8 wk after completion of treatment. RESULTS: After completion of therapy, 194/257 patients showed negative 13C-urea breath test results. According to intention-to-treat analysis, the infection was eradicated in 93/129 (72.1%) patients in group A and 101/128 (78.9%) in group B (P = 0.204). Per-protocol analysis showed successful eradication in 93/118 (78.8%) patients from group A and 101/114 (88.6%) from group B (P = 0.044). There were no significant differences in the side effects experienced by the patients in the two treatment groups. CONCLUSION: Our results suggest that the addition of ecabet sodium improves the efficacy of the standard triple therapy for H pylori. 相似文献
20.
Yi-Qi Du Tun Su Jian-Gao Fan Yu-Xia Lu Ping Zheng Xing-Hua Li Chuan-Yong Guo Ping Xu Yan-Fang Gong Zhao-Shen Li 《World journal of gastroenterology : WJG》2012,18(43):6302-6307
AIM:To investigate whether the addition of probiotics can improve the eradication effect of triple therapy for Helicobacter pylori (H. pylori ) infection. METHODS:This open randomized trial recruited 234 H. pylori positive gastritis patients from seven local centers. The patients were randomized to one-week standard triple therapy (omeprazole 20 mg bid , clarithromycin 500 mg bid , and amoxicillin 1000 mg bid ; OCA group, n = 79); two weeks of pre-treatment with probiotics, containing 3 × 107 Lactobacillus acidophilus per day, prior to one week of triple therapy (POCA group, n = 78); or one week of triple therapy followed by two weeks of the same probiotics (OCAP group, n = 77). Successful eradication was defined as a negative C13 or C14 urease breath test four weeks after triple therapy. Patients were asked to report associated symptoms at baseline and during follow-up, and side effects related to therapy were recorded. Data were analyzed by both intention-to-treat (ITT) and per-protocol (PP) methods. RESULTS:PP analysis involved 228 patients, 78 in the OCA, 76 in the POCA and 74 in the OCAP group. Successful eradication was observed in 171 patients; by PP analysis, the eradication rates were significantly higher (P = 0.007 each) in the POCA (62/76; 81.6%, 95% CI 72.8%-90.4%) and OCAP (61/74; 82.4%, 95% CI 73.6%-91.2%) groups than in the OCA group (48/78; 61.5%, 95% CI 50.6%-72.4%). ITT analysis also showed that eradication rates were significantly higher in the POCA (62/78; 79.5%, 95% CI 70.4%-88.6%) and OCAP (61/77; 79.2%, 95% CI 70%-88.4%) groups than in the OCA group (48/79; 60.8%, 95% CI 49.9%-71.7%), (P = 0.014 and P = 0.015). The symptom relieving rates in the POCA, OCAP and OCA groups were 85.5%, 89.2% and 87.2%, respectively. Only one of the 228 patients experienced an adverse reaction. CONCLUSION:Administration of probiotics before or after standard triple therapy may improve H. pylori eradication rates. 相似文献